Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib (original) (raw)

• Sehn LH . Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 2006, 295–302.
  Article Google Scholar
• Andrew T, Lister BC, Armitage JO . Non-Hodgkin's lymphoma. In: Martin D. Abeloff, James O. Armitage JEN, Michael B. Kastan, W. Gillies McKenna (eds). Clinical Oncology. (e 3rd edn) Churchill Livingstone: Philadelphia PA, 2004, pp 3015–3076.
  Google Scholar
• De Paepe P, De Wolf-Peeters C . Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007; 21: 37–43.
  Article CAS PubMed Google Scholar
• Abramson JS, Shipp MA . Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164–1174.
  Article CAS PubMed Google Scholar
• Coiffier B . Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603–3613.
  Article CAS PubMed Google Scholar
• Kuppers R . Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251–262.
  Article PubMed Google Scholar
• Rodriguez A, Villuendas R, Yanez L, Gomez ME, Diaz R, Pollan M et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007; 21: 1984–1991.
  Article CAS PubMed Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J . B cell antigen receptor signaling 101. Mol Immunol 2004; 41: 599–613.
  Article CAS PubMed Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
  Article CAS PubMed Google Scholar
• Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.
  Article PubMed Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996.
  Article CAS PubMed PubMed Central Google Scholar
• Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861.
  Article CAS PubMed Google Scholar
• Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74.
  Article CAS PubMed Google Scholar
• Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB . Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002; 277: 31781–31788.
  Article CAS PubMed Google Scholar
• Anagostopoulos I, Dallenbach F, Stein H . Diffuse large cell lymphomas. In: Knowles DM (ed). Neoplastic Hematopathology, 2nd edn, Lippincott Williams &Wilkins: Philadelphia, PA, 2001, pp 855–913.
  Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
  Article CAS PubMed Google Scholar
• Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470.
  Article PubMed Google Scholar
• Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM . Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006; 130: 1819–1824.
  PubMed Google Scholar
• Salazar EP, Rozengurt E . Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397. J Biol Chem 2001; 276: 17788–17795.
  Article CAS PubMed Google Scholar
• Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115: 369–378.
  Article CAS PubMed PubMed Central Google Scholar
• Spreafico A SS, Serchi T, Orlandini M, Angelucci A, Magrini D, Bernardini G et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]p yrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 2008 2008; 22: 1560–1571.
  Article PubMed Google Scholar
• Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G et al. Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 2007; 26: 4179–4188.
  Article CAS PubMed Google Scholar
• Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken JH et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005; 105: 2916–2923.
  Article CAS PubMed Google Scholar
• Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723.
  Article CAS PubMed Google Scholar
• Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996; 15: 2685–2694.
  Article CAS PubMed PubMed Central Google Scholar
• Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996; 379: 349–353.
  Article CAS PubMed Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, Levy R . Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006; 177: 1581–1589.
  Article CAS PubMed Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ . Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924–6932.
  Article CAS PubMed Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473–481.
  Article CAS PubMed Google Scholar
• Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014–3022.
  Article CAS PubMed Google Scholar
• Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007; 6: 1962–1972.
  Article CAS PubMed Google Scholar
• Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/‘triple-negative’ breast cancer cell lines growing in vitro . Breast Cancer Res Treat 2007; 105: 319–326.
  Article CAS PubMed Google Scholar
• Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908–3914.
  Article CAS PubMed Google Scholar
• Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011–11016.
  Article CAS PubMed PubMed Central Google Scholar
• Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J et al. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene 2006; 25: 5056–5062.
  Article CAS PubMed Google Scholar